A computational approach to the study of the binding mode of dual ACE/NEP inhibitors
- PMID: 20170101
- DOI: 10.1021/ci9005047
A computational approach to the study of the binding mode of dual ACE/NEP inhibitors
Abstract
Combined blockade of the renin-angiotensin-aldosterone system (RAAS) is an attractive therapeutic strategy for the treatment of cardiovascular diseases. Vasopeptidase inhibitors are a group of compounds capable of inhibiting more than one enzyme, which leads to potentiation of natriuretic peptide actions and suppression of the RAAS. In this study, molecular modeling has been used to elucidate key structural features that govern the binding and/or selectivity of a single compound toward the zinc catalytic sites of the N- and C-domains of the angiotensin-converting enzyme (ACE) and the neutral endopeptidase (NEP). Eleven dual inhibitors were categorized in three classes, according to their zinc binding groups. Analysis of their docked conformers revealed the molecular environment of the catalytic sites and the specific interactions between the inhibitors and amino acid residues that are important for selectivity and cooperativity. In addition, inhibitors were predicted to bind to the C-domain of the ACE with greater affinity than the N-domain, with an average difference in the free energy of binding approximately 2-3 kcal mol(-1). Residues that were identified to actively participate in the binding and stabilizing of the enzyme-inhibitor complexes were analyzed in a consensus way for both the ACE and the NEP. These atomic-level insights into enzyme-ligand binding can be used to drive new structure-based drug design processes in the quest for more selective and effective vasopeptidase inhibitors.
Similar articles
-
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.J Med Chem. 1996 Mar 15;39(6):1210-9. doi: 10.1021/jm950590p. J Med Chem. 1996. PMID: 8632427
-
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.Bioorg Med Chem Lett. 2009 Aug 15;19(16):4715-9. doi: 10.1016/j.bmcl.2009.06.064. Epub 2009 Jun 21. Bioorg Med Chem Lett. 2009. PMID: 19596577
-
Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.Biochemistry. 2004 Jun 29;43(25):8048-54. doi: 10.1021/bi049504q. Biochemistry. 2004. PMID: 15209500
-
Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.J Hypertens. 2007 Jan;25(1):25-35. doi: 10.1097/HJH.0b013e3280113950. J Hypertens. 2007. PMID: 17143168 Review.
-
Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.Pathol Biol (Paris). 1998 Mar;46(3):191-200. Pathol Biol (Paris). 1998. PMID: 9769915 Review.
Cited by
-
Advances in the structural basis for angiotensin-1 converting enzyme (ACE) inhibitors.Biosci Rep. 2024 Aug 28;44(8):BSR20240130. doi: 10.1042/BSR20240130. Biosci Rep. 2024. PMID: 39046229 Free PMC article. Review.
-
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.Pharmacol Rev. 2019 Oct;71(4):539-570. doi: 10.1124/pr.118.017129. Pharmacol Rev. 2019. PMID: 31537750 Free PMC article. Review.
-
Proposed Bioactive Conformations of Opiorphin, an Endogenous Dual APN/NEP Inhibitor.ACS Med Chem Lett. 2011 Nov 17;3(1):20-4. doi: 10.1021/ml200182v. eCollection 2012 Jan 12. ACS Med Chem Lett. 2011. PMID: 24900367 Free PMC article.
-
Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies.J Chem Inf Model. 2011 May 23;51(5):1074-82. doi: 10.1021/ci200083f. Epub 2011 Apr 26. J Chem Inf Model. 2011. PMID: 21520937 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous